Can frugal Valeant keep 'pipeline in a drug' Botox pumping up new uses?

Botox is more than just a blockbuster product these days. It's a lure for would-be Allergan ($AGN) buyer Valeant Pharmaceuticals ($VRX). And it's one of the few drugs that Valeant thinks is worth some significant R&D investment. But would that frugal company spend enough to keep pumping out new indications--and new marketing avenues? Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.